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Abstract 
Purpose
To assess the ef  cacy of immunomodulatory therapy in achieving remission and long-term control of in  am-
mation in patients with multiple sclerosis-associated uveitis.
Methods
We did a retrospective case series study on the clinical records of 10 patients with uveitis and multiple sclero-
sis, treated at the Massachusetts Eye Research and Surgery Institution. The period of study was from July 2005 
until November 2012. The evaluation of effectiveness was based on the control of intraocular in  ammation.
Results
All patients were female, white, with mean age 49.3 years. Intermediate uveitis was diagnosed in 6 cases 
(60%), panuveitis – in 3 (30%), posterior – in 1 (10%). Bilateral involvement was present in all (100%) pa-
tients. Immunomodulatory medications as monotherapy included methotrexate - in 5 (50%), mycophenolate 
mofetil – in 4 (40%), daclizumab – in 2 (20%), cyclophosphamide – in 2 (20%), methotrexate - in 1 (10%), 
and cyclosporin - in 1 (10%) patient. Combined therapy was used with mycophenolate mofetil and cyclosporin 
in 4 cases (40%), cyclosporin and azathioprine – in 2 (20%), and methotrexate and cyclosporin – in 1 (10%). 
Corticosteroids were used by all patients. Seven patients (70%) had systemic therapy for multiple sclerosis with 
Glatiramer acetate in 3 (30%) of them, interferon beta-1a – in 3 (30%), and interferon beta-1b – in 1 (10%). At 
the end of follow-up, 1 patient (10%) was in remission for 19 months following azathioprine therapy, 2 (20%) 
– quiescent with no immunomodulatory therapy or corticosteroids for 6 and 12 months, with no previous stable 
remission, 1 (10%) – stable on mycophenolate mofetil and cyclosporin for 21 months, 2 (20%) – maintained on 
immunomodulatory therapy and corticosteroids for 8 and 37 months, 5 eyes of 3 patients – quiescent after  uo-
cinolone acetonide intravitreal implant for as long as 60 months, 3 eyes of 2 patients had signs of active disease.
Conclusions
Non-corticosteroid conventional systemic immunomodulatory medications can maintain long-term control 
of intraocular inframmation in multiple sclerosis - associated uveitis. The speci  c multiple sclerosis disease-
modifying drugs in our study, which were IFN beta-1b, IFN beta-1a, and glatiramer acetate, were ef  cacious for 
the management of the non-ocular manifestations of MS but we could not demonstrate a de  nitive bene  t in the 
control of ocular  in  ammation, prevention of complications, and steroid-sparing.
Key words: multiple sclerosis, uveitis, immunomodulatory therapy
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Introduction
Multiple sclerosis (MS) is an autoimmune 
in  ammatory condition of unknown etiology, 
characterized by the development of plaques 
of demyelination in the central nervous system 
(CNS) [23]. Continued demyelination leads to 
axonal loss and progression of clinical symp-
toms. 
The mean age of the  rst MS episode has been 
shown to be 30 years and observations indicate 
a predilection for the female gender [26]. Preva-
lence varies geographically, being rare in equa-
torial regions and commoner in higher latitudes 
in either hemisphere. 
The etiology of MS is still unclari  ed. No 
infectious agent has been demonstrated conclu-
sively thus far; though, viral and bacterial causes 
have been suspected. Available data indicate a 
complex interplay between environmental (sun-
light exposure, vitamin D) and genetic factors 
[6,13,23,25,29]. 
With regard to the occurence and progression 
of the demyelination in MS, it has been pro-
posed that abnormal T-cell regulation may lead 
to an autoin  ammatory response [38]. Subsets of 
CD4+ T-cells, namely Th17 cells and regulatory 
T cells, have been implicated in the autoimmune 
response in MS. Increased expression of inter-
leukin (IL)-17 has been shown in microarray 
analysis of serum from MS patients [96], and the 
development of experimental autoimmune en-
cephalitis, the animal model for MS, was signi  -
cantly suppressed in IL-17-/- de  cient mice [16]. 
Activated in  ammatory cells reach the CNS 
through postcapillary venules in the settings of 
increased permeability of the blood-brain barrier 
and target oligodendrocytes via myelin-related 
proteins such as myelin basic protein and my-
elin oligodendrocyte glycoprotein [13]. Result-
ant axonal damage has been associated with an 
increased in  ammatory response [36]. 
Myelin is not a  normal structural component 
in the human retina but, nevertheless, in  amma-
tion with disruption of the blood-retinal barrier 
and neuronal and axonal loss have been demon-
strated in the setting of multiple sclerosis [8, 10, 
32, 33, 34].
The frequency of uveitis in patients with MS 
varies from 0.4% to 26.9% [1,4,5,9,28]. Any 
anatomical subtype [14] of uveitis has been ob-
served. It is well known that intraocular in  am-
mation may develop as late as 17 years follow-
ing the onset of MS [40], therefore the longer 
the follow-up, the higher the prevalence. Vari-
ous authors estimate the prevalence of MS in 
the total uveitic population to be around 1–2% 
[4,9,19,30] with a higher prevalence in patients 
with intermediate uveitis, from 7.8% to 14.8% 
[7,18,27,40]. Rodriguez and Foster have found 
the the prevalence of MS in patients with uveitis 
was 1.3%, and 8% in the subgroup of patients 
with intermediate uveitis [31].
By far, with respect to therapy, multiple class-
es and ways of application of medications have 
been employed, to no absolute success. Glu-
cocorticoids, such as systemic prednisone and 
adrenocorticotropic hormone, may ameliorate 
many of the symptoms of MS by decreasing in-
 ammation, but they have not been shown to in-
duce remission [2]. Azathioprine, methotrexate, 
sulfasalazine, and cyclophosphamide have dem-
onstrated variable and moderate ef  cacy at most 
[20,22,24,37].  
At present, disease-modifying drugs (DMDs) 
represent the staple for long-term therapy for 
MS [21]. Interferon therapy (IFN-beta1b and 
IFN-beta1a) has been demonstrated to reduce by 
about 30% the rate of relapses in active relaps-
ing-remitting MS and, in addition, reduce lesion 
accumulation on MRI [11]. In a similar fashion, 
Glatiramer acetate (GLAT) was noted to cause 
a 29% reduction in relapse rate over 2 years in 
relapsing-remitting MS [15]. Monoclonal anti-
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bodies have also been increasingly used in the 
therapy of MS [21].  Addition of daclizumab to 
interferon therapy has been shown to reduce the 
occurence of new MRI lesions [39]. 
In view of the above, no de  nitive and speci  c 
guidelines have been devised for the treatment of 
uveitis, associated with MS. 
Purpose
To assess the ef  cacy of immunomodulatory 
therapy in achieving remission and long-term 
control of in  ammation in patients with multiple 
sclerosis-associated uveitis. Secondly, to evalu-
ate the contribution of MS-speci  c disease-mod-
ifying drugs to the control of in  ammation.
Material and Methods
We did  a retrospective, observational study 
on the clinical records of 10 patients with uveitis 
and multiple sclerosis, treated for uveitis at the 
Massachusetts Eye Research and Surgery Institu-
tion (MERSI). The period of study was from July 
2005 until November 2012. 
Inclusion criteria included: 
1. De  nitive diagnosis of multiple sclerosis
2. De  nitive association between the uveit-
ic entity and MS
3. Immunomodulatory therapy during the 
course of treatment
4. Minimal follow-up period of 12 months 
Exclusion criteria:
1. Uncertain diagnosis of MS
2. Uveitis of other causes, i.e. infectious/au-
toimmune, concurrent with MS
3. No immunomodulatory treatment for the 
MS-associated uveitis
4. Follow-up period less than 12 months 
For the accomplishment of the primary 
purpose, the following objectives were set:
1. Primary objective – corticosteroid-free 
remission for at least 12 months following remis-
sion induction and subsequent discontinuation of 
uveitis-speci  c immunomodulatory therapy
2. Secondary objective – corticosteroid-free 
remission for at least 12 months on continuing 
uveitis-speci  c immunomodulatory therapy
3. Tertiary objective – long-term control of 
in  ammation with any therapeutic regimens in-
cluding corticosteroids
The role of MS disease-modifying drugs was 
additionally assessed in all patients, in whom 
their use was documented.
Collected data included demographic charac-
teristics at presentation, duration of uveitis/MS 
prior to presentation, type of uveitis and activ-
ity at presentation, associated ocular conditions 
at presentation, ocular complications during 
follow-up, ocular surgical procedures and out-
comes, MS-associated non-ocular manifesta-
tions, therapy prior to presentation, during the 
follow-up period and outcomes of therapy, in-
cluding IMT, MS disease-modifying drugs, cor-
ticosteroids, other medications/surgeries, best-
corrected visual acuity on initial exam and on the 
last follow-up.
Clinical assessment was based on a complete 
ophthalmologic exam (BCVA, intraocular pres-
sure measurement, slit-lamp examination, and 
dilated fundus exam), and  uorescein angiogra-
phy to further evaluate changes related to vascu-
litis. Anterior chamber in  ammation was graded 
according to the classi  cation established by the 
Standardization of Uveitis Nomenclature, and 
the National Eye Institute system was used for 
grading vitreous in  ammation.
The change in the grade and degree of intraoc-
ular in  ammation was used to assess treatment 
success or failure.
Informed consent was obtained from all partic-
ipants, as well as an institutional board approval. 
All the proceedings followed the tenets of the 
Declaration of Helsinki. 
Statistical evaluation was done with descrip-
tive statistical methods.
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Results
All patients were female, white-caucasian. The 
age of presentation at our institution varied from 
42 to 59 years. The mean age was 49.3 years. Nine 
patients (90%) were referred with an already es-
tablished diagnosis of uveitis, whereas 1 patient 
(10%) had a new onset uveitis. The duration of in-
traocular in  ammation prior to the initial exam at 
MERSI ranged from 12 to 25 years. On presenta-
tion, MS had been diagnosed in 7 patients (70%), 
while in 3 (30%) - during our monitoring. MS was 
diagnosed as relapsing-remitting in all patients. 
The follow-up period was from 36 to 90 months, 
mean - 70.4 months [Table 1]. 
On initial examination, active uveitis was ob-
served in 6 (60%) and quiescent in 4 (40%) pa-
tients. Among those, who were quiet on presenta-
tion, 1 patient (25%) was on azathioprine (AZA) 
for 8 months, 1 (25%) - on interferon beta-1a 
(IFN beta-1a), topical prednisolone acetate 1% 
and  a nonsteroidal antiin  ammatory medication 
(NSAID) for 34 months, 1 (25%) - on IFN beta-1a 
and an NSAID for 36 months, and 1 (25%) had no 
recent medication history [Table 1].
Anatomically, intermediate uveitis was diag-
nosed in 6 cases (60%), panuveitis – in 3 (30%), 
posterior uveitis – in 1 (10%). Bilateral involve-
ment was present in all (100%) patients [Table 1]. 
Table 1: Demographic data, type, activity, and therapy of uveitis on the initial exam. 
Abbreviations: AZA – azathioprine; IFN-beta-1a – interferon beta-1 alpha; NSAID – nonsteroidal 
antiinfl ammatory drug; PA – prednisolone acetate ophthalmic suspension 1%.
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On presentation, concurrent ocular conditions 
included history and signs of previous optic neu-
ritis in 5 eyes of 4 patients, 3 of which with signs 
of optic atrophy. One of the patients had posterior 
uveitis and 3 (30%)– intermediate. Cataract was 
noted in 4 eyes of 3 patients, one with panuvei-
tis, and 2 – with intermediate uveitis. Nine eyes 
of 5 patients, one of whom had posterior uveitis, 
the other 4 – intermediate, were pseudophakic. 
Secondary glaucoma was observed in 1 patient 
with intermediate uveitis and 1 with panuveitis 
was a glaucoma suspect. Macular edema (ME) 
was found in 8 eyes of 5 patients, 2 with panu-
veitis and 3 - with intermediate. Seven eyes of 4 
patients were status post pars plana vitrectomy 
(PPV), 3 with intermediate uveitis and 1 – with 
panuveitis [Table 2].
Structural and functional ocular complica-
tions, noted during the course of the follow-up 
period, comprised of ME in 6 eyes of 4 patients 
- 2 with intermediate uveitis, 1 – with posterior 
uveitis, and 1 – with panuveitis. Epiretinal mem-
brane was observed in 1 patient with intermedi-
ate uveitis. Transitory ocular hypertension was 
documented in 1 patient with panuveitis. One pa-
tient with panuveitis was diagnosed with second-
ary glaucoma, and one case of intermediate uvei-
tis, who already had glaucoma on presentation 
worsened, necessitating Ahmed valve implanta-
tion, which was successful. Cataract developed 
in 5 eyes of 3 patients, 2 with panuveitis and 1 
with intermediate uveitis. Progression of previ-
ously diagnosed cataract was noted in 4 eyes of 3 
patients. Overall, 6 eyes of 5 patients underwent 
uncomplicated cataract extraction and second-
ary intraocular lens implantation. Two patients 
with ME had bilateral intravitreal bevacizumab 
injections, one of them twice. One of those had 
an intraviteral triamcinolone acetonide injection. 
Intravitreal injections were not associated with 
exacerbation of in  ammation. One patient with 
intermediate uveitis had a PPV with endolaser 
for a retinal tear, which was uneventful [Table 2].
During the follow-up period, different medi-
cations were used in  each patient at different 
points in time. Immunomodulatory medications 
(IMT) as monotherapy included azathioprine in 
1 patient (10%), methotrexate - in 5 (50%), my-
cophenolate mofetil – in 4 (40%), cyclosporin 
– in 1 (10%), daclizumab – in 2 (20%), and cy-
clophosphamide – in 2 (20%). Combined therapy 
was used with mycophenolate mofetil and cyclo-
sporin in 4 cases (40%), cyclosporin and azathio-
prine – in 2 (20%), and methotrexate and cyclo-
sporin – in 1 (10%). Corticosteroids by various 
routes were utilized in all patients (100%). Six 
patients (60%) were corticosteroid-dependent at 
the end of follow-up.  
Seven patients (70%) had systemic therapy 
speci  c for MS. Glatiramer acetate was used in 3 
(30%) of them, interferon beta-1a – in 4 (40%), 
and interferon beta-1b – in 1 (10%). 
Individual patient data, comprising uveitis 
subtype, type, duration and outcomes of therapy 
are listed below in Table 3:
Our primary objective of a state of remission for 
at least 12 months without immunomodulatory 
therapy for the ocular disease, nor corticosteroid 
use, was achieved by 3 patients (30%). Among 
them, at the end of follow-up, 1 patient (10%), 
''A'', with intermediate uveitis was in remission 
for 19 months following AZA monotherapy and 
no corticosteroids for at least 24 months. She was 
still continuing on glatiramer acetate (GLAT), 
peroral di  unisal and topical bromfenac sodium. 
Duration of AZA therapy was 58 months and that 
of GLAT – 43 months. During the course of her 
ocular disease, she had had 5 relapses of in  am-
mation, managed by corticosteroids, reactivation 
of ME in one eye, and cataract extraction in one 
eye.
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Table 2. Concurrent ocular conditions, complications, and surgery on presentation and follow-up
Abbreviations:  BV – bevacizumab; CE – cataract extraction,; EL – endolaser;  ivt – 
intravitreal; ME  – macular edema; PPV – pars plana vitrectomy;TAC – triamcinolone.
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Table 3. Therapy of MS-associated uveitis
Abbreviations: AZA – azathioprine; CSA – ciclosporin A; CTX – cyclophosphamide; DAC – 
daclizumab; IFN – interferon; IVFA – intravitreal  uocinolone acetonide; GLAT – glatiramer 
acetate; MMF – mycophenolate mofetil; MTX – methotrexate; PA – prednisolone acetate 
ophthalmic suspension 1%.
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One patient (10%), ''G'', with intermediate 
uveitis was quiescent for 12 months without any 
medications for her eyes or general MS condi-
tion. Prior therapy had been with mycophenolate 
mofetyl (MMF) and cyclosporine (CSA) com-
bination for 16 months and MMF monotherapy 
for 15 months, and also intravenous methotrex-
ate (MTX). She had had 2  ares of in  ammation 
and ME in both eyes, and had a cataract extrac-
tion in one eye. Corticosteroids had been used 
by topical and intravenous route. Another patient 
(10%), ''J'', with intermediate uveitis, following a 
10-month course of MTX with concurrent corti-
costeroid use, had been later stable for 26 months 
on IFN beta-1a and an NSAID only, before she 
had another  are-up, adressed by intravenous 
methylprednisolone infusion. Further, patient 
had cataract extraction in one eye and PPV with 
endolaser for retinal tear in the same eye.
The secondary objective of remission, main-
tained with IMT, without concurrent corticoster-
oid use for at least 12 months, was accomplished 
in 1 (10%) patient with posterior uveitis. At the 
end of follow-up, patient ''C'' was in a 21-month 
corticosteroid-free remission on a combination 
of MMF, CSA, and topical  urbiprofen for the 
ocular disease, and IFN beta-1a for MS. She 
had previously failed peroral MTX due to side 
effects (7 months) and MMF monotherapy (12 
months), secondary to active in  ammation. IFN 
beta-1a had been used for 86 months. Complica-
tions included ME in one eye.
The tertiary objective of long-term control of 
in  ammation by ''any reasonable means'', con-
sidering the inherent progressive nature of MS, 
was met by 5 patients, 9 eyes in total (45%). One 
patient (10%), ''B'', with intermediate uveitis was 
quiescent for 8 months on a combination of CSA, 
topical prednisolone acetate 1%  and IFN beta-
1a. Duration of CSA therapy was 55 months and 
that of IFN beta-1a – 90 months. Corticosteroids 
were used throughout the follow-up period. One 
patient (10%), ''I'', with panuveitis in both eyes 
had been quiet on peroral MTX and peroral/
topical corticosteroids, for 37 months.The same 
patient, 8 weeks following institution of IFN be-
ta-1b had a coincident recurrence of ME in one 
eye without de  nitive signs of uveitic in  amma-
tion. Also, she had previously failed one month 
course of MMF. Disease course had been com-
plicated by bilateral cataract and ME. Patient had 
undergone a diagnostic PPV, which was associ-
ated with 4 months of in  ammation quiescence. 
Three patients (30%) with recalcitrant uveitis 
had a  uocinolone acetonide intraviteral implant 
(IVFA). Out of them, one patient (10%), ''D'', 
with intermediate uveitis was quiescent for 25 
months following bilateral implantation and con-
current IFN beta-1a. She had previously failed 
daclizumab (DAC) due to inadequate control of 
in  ammation (11 months of therapy), CSA and 
AZA combination (1 month), and intravenous 
cyclophosphamide (CTX) (7 months). She had 
an exacerbation of ME in both eyes which was 
followed by bilateral bevacizumab injections, 
and worsening of glaucoma in one eye with sub-
sequent Ahmed valve implantation. Another pa-
tient (10%), ''F'', with bilateral panuveitis had in-
active in  ammation for 60 months after bilateral 
IVFA and long-term systemic celecoxib use. Pri-
or to that, she had not responded to MMF mon-
otherapy (2 months), addition of CSA (side ef-
fects), and DAC (11 months). She had transitory 
ocular hypertension and progression of cataracs 
in both eyes with subsequent successful cataract 
surgery. One patient (10%), ''E'', with intermedi-
ate uveitis had excellent control of in  ammation 
in one eye following an IVFA for 29 months and 
active in  ammation in the other eye. Twenty-one 
months of GLAT therapy in the given patient did 
not lead to improvement of ocular in  ammation.
At the time of the last follow-up exam, 3 eyes 
of 2 patients had signs of active in  ammation. 
One of them, patient ''H'', with bilateral panu-
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veitis, was on GLAT, with a duration of therapy 
12 months, and topical prednisolone acetate. 
She had failed peroral MTX monotherapy (12 
months) and a combination of MTX and CSA 
(4 months). Intravitreal triamcinolone acetonide 
had also been employed once in one eye. Ocu-
lar complications included bilateral cataract and 
secondary glaucoma in one eye. Cataract surgery 
to the eye with glaucoma was uneventful and im-
proved visual acuity. The other patient, ''E'' with 
active intermediate uveitis in one eye had been 
on GLAT for 21 months and had also failed to 
respond to combinations of MMF and CSA (2 
months), CSA and AZA (24 months), and intra-
venous CTX (6 months). Further, she had had 
intravitreal bevacizumab injections  and perio-
cular and intraocular triamcinolone to both eyes. 
Epiretinal membrane formation in both eyes was 
noted during follow-up.
With respect to non-ocular manifestations of 
MS, three patients (30%) had no associated com-
plaints during follow-up. Two of them (20%) had 
been on IFN beta-1a since the onset of follow-up, 
whereas one (10%) was on GLAT for 43 months. 
Moreover, 3 patients (30%) had sensory distur-
bance, 3 (30%) - pain in various loci, 2 (20%) 
- psychiatric and cognitive disturbance, 1 (10%) 
- blurry vision due to optic neuritis, and 1 (10%) 
- diplopia. All of the above were not directly as-
sociated with episodes of active ocular in  am-
mation and most, including the optic neuritis and 
the diplopia, resolved following institution of 
MS-speci  c disease-modifying agents.
Discussion
In the present retrospective case-series study, 
we presented the effects of immunomodulatory 
therapy with mostly conventional ''immunosup-
presive'' medications and MS disease modifying 
agents, including IFN beta-1a, IFN beta- on the 
activity of intraocular in  ammation.
As mentioned earlier, various classes of drugs 
have been employed in the therapeutic approach 
to patients with MS-associated pathology. Stud-
ies, evaluating the ef  cacy of therapeutic modali-
ties for the ocular manifestations of MS in partic-
ular, have been scarce in the available literature. 
Presently,  MS-associated uveitis is managed in 
a similar way to noninfectous idiopathic uveitis 
of presumed autoimmune etiology. A stepladder 
approach, beginning with NSAIDs and advanc-
ing to IMT with various agent has been recom-
mended as a reasonable treatment strategy [12]. 
Therapy in our patients was based on the 
aforementioned stepladder approach. Treatment 
failure was not infrequent and 60% of patients 
have failed three different IMT regimens. Nev-
ertheless, three patients (30%) with intermediate 
uveitis had achieved corticosteroid-free remis-
sion of at least 12 months following IMT admin-
istration and discontinuation. One of them  had 
used AZA for 53 months, 1 patient had been on 
MMF and CSA for 16 months and subsequently 
MMF monotherapy for 15 months, and the third 
– on peroral MTX and CSA for 10 months.  Cor-
ticosteroid-free remission for at least 12 months 
while on IMT was achieved in one patient with 
posterior uveitis, who was in a 21-month remis-
sion on a combination of MMF, CSA, and topical 
 urbiprofen. 
Long-term control of in  ammation without 
reaching corticosteroid-free state was achieved in 
9 eyes of 5 patients. One patient with panuveitis 
in both eyes had been quiet on peroral MTX and 
peroral/topical corticosteroids for 37 months. A 
patient with intermediate uveitis was quiescent 
for 8 months on a combination of CSA and topi-
cal prednisolone acetate 1% . Three patients with 
recalcitrant uveitis had a  uocinolone acetonide 
intraviteral implant and had been quiescent for 
25 (two eyes), 60 (two eyes), and 29 months (one 
eye) months.
At the last follow-up exam, 3 eyes of 2 pa-
tients had signs of active in  ammation. One of 
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them, with bilateral panuveitis, was on GLAT, 
with a duration of therapy 12 months, and topical 
prednisolone acetate. She had previously failed 
peroral MTX monotherapy for 12 months, and a 
combination of MTX and CSA for 4 months. In-
travitreal triamcinolone acetonide had also been 
done to one eye. The other patient had intermedi-
ate uveitis, active in one eye, and she had been 
on GLAT for 21 months and had also failed to 
respond to combinations of MMF and CSA for 2 
months, CSA and AZA for 24 months, and intra-
venous cyclophosphamide for 6 months. 
The role of the MS disease-modifying medica-
tions in the induction of remission and maintain-
ing control of in  ammation was controversial. 
Glatiramer acetate and IFN beta-1a had been 
used for 43 and 26 months, respectively, in the 
therapeutic regimen in two of the three patients 
who had an IMT and corticosteroid-free remis-
sion period of at least 12 months. Interferon beta-
1a was also used for 86 months in a patient stable 
on IMT for at 21 months. A stable patient with 
a bilateral  uocinolone acetonide implant was 
also on interferon beta-1a. Interferon beta-1b in 
a different patient did not prevent development 
of macular edema in the setting of presumably 
quiescent in  ammation. The two patients, active 
on the most recent follow-up exam, had been on 
GLAT for 12 and 21 months respectively, with-
out apparent bene  t of this medication on control 
of in  ammation and relapse rate. 
Becker, Heiligenhaus and al., had previously 
demonstrated a bene  cial effect of IFN beta-1a 
on MS-associated uveitis in a non-randomised, 
retrospective observational case series in 2005. 
Their study comprised of 24 eyes of 13 patients 
with a mean duration of treatment 24.6 month. 
Improvement of visual acuity was noted in 17 
eyes, decrease in in  ammation in all eyes, and 
a resolution of ME in 9 out of 13 eyes with this 
complication [3]. 
From our results we could not determine with 
certainty whether IFN beta-1a had any bene  cial 
effect on intraocular in  ammation. Besides, a pa-
tient on IFN beta-1a still had to receive an IVFA 
implant. On the other hand, glatiramer acetate, 
despite showing some promising results in ani-
mal studies for treating allergic encephalomyeli-
tis [35], was apparently ineffectual for managing 
uveitis in our group of patients. Nevertheless, 
MS disease-modifying drugs, were effective in 
addressing the non-ocular manifestations of MS 
that we encountered. 
Conclusion
Uveitis, associated with multiple sclerosis, is 
characterized by a protracted and complicated 
clinical course. Non-corticosteroid conventional 
systemic immunomodulatory medications can 
induce and maintain corticosteroid-free remis-
sion. In the event of  systemic therapy failure, the 
intravitreal  uocinolone acetonide implant may 
present an alternative in recalcitrant cases, con-
sidering all the possible complications from the 
implant itself. 
The speci  c multiple sclerosis disease-modi-
fying drugs in our study, which were IFN beta-
1b, IFN beta-1a, and glatiramer acetate, were ef-
 cacious for the management of the non-ocular 
manifestations of MS but we could not demon-
strate a de  nitive bene  t in the control of ocular 
in  ammation, prevention of complications, and 
steroid-sparing.
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